The Role of Infiltrated T Lymphocyte in Oral Squamous Cell Carcinoma: Insights into Clinicopathological Characteristics and Prognosis

References

• Gharat SA, Momin M, Bhavsar C. Oral squamous cell carcinoma: current treatment strategies and nanotechnology-based approaches for prevention and therapy. Crit Rev Ther Drug. 2016;33(4):363–400. doi:10.1615/CritRevTherDrugCarrierSyst.2016016272
   PubMed Web of Science ®Google Scholar
• Bugshan A, Farooq I. Oral squamous cell carcinoma: metastasis, potentially associated malignant disorders, etiology and recent advancements in diagnosis. F1000Res. 2020;9:229. doi:10.12688/f1000research.22941.1
   PubMedGoogle Scholar
• Sasahira T, Kirita T. Hallmarks of Cancer-Related Newly Prognostic Factors of Oral Squamous Cell Carcinoma. Int J Mol Sci. 2018;19(8). doi:10.3390/ijms19082413
   Web of Science ®Google Scholar
• Jiang M, Li B. STAT3 and its targeting inhibitors in oral squamous cell carcinoma. Cells-Basel. 2022;11:19.
   Web of Science ®Google Scholar
• Mughees M, Sengupta A, Khowal S, Wajid S. Mechanism of tumour microenvironment in the progression and development of oral cancer. Mol Biol Rep. 2021;48(2):1773–1786. doi:10.1007/s11033-020-06054-6
   PubMed Web of Science ®Google Scholar
• Pignatelli P, Romei FM, Bondi D, Giuliani M, Piattelli A, Curia MC. Microbiota and oral cancer as a complex and dynamic microenvironment: a narrative review from etiology to prognosis. Int J Mol Sci. 2022;23(15):8323. doi:10.3390/ijms23158323
   PubMed Web of Science ®Google Scholar
• Ai R, Tao Y, Hao Y, et al. Microenvironmental regulation of the progression of oral potentially malignant disorders towards malignancy. Oncotarget. 2017;8(46):81617–81635. doi:10.18632/oncotarget.20312
   PubMedGoogle Scholar
• Eckert AW, Wickenhauser C, Salins PC, Kappler M, Bukur J, Seliger B. Clinical relevance of the tumor microenvironment and immune escape of oral squamous cell carcinoma. J Transl Med. 2016;14(1):85. doi:10.1186/s12967-016-0828-6
   PubMedGoogle Scholar
• Gannot G, Gannot I, Vered H, Buchner A, Keisari Y. Increase in immune cell infiltration with progression of oral epithelium from hyperkeratosis to dysplasia and carcinoma. Br J Cancer. 2002;86(9):1444–1448. doi:10.1038/sj.bjc.6600282
   PubMed Web of Science ®Google Scholar
• Strauss L, Bergmann C, Szczepanski M, Gooding W, Johnson JT, Whiteside TL. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res. 2007;13(15 Pt 1):4345–4354. doi:10.1158/1078-0432.CCR-07-0472
   PubMed Web of Science ®Google Scholar
• Flores-Hidalgo A, Murrah V, Fedoriw Y, Padilla RJ. Relationship of infiltrating intraepithelial T lymphocytes in the diagnosis of oral lichen planus versus oral epithelial dysplasia: a pilot study. Or Surg or Med or Pa. 2019;127(6):e123–e135. doi:10.1016/j.oooo.2019.02.004
   Google Scholar
• Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer. 2016;4(1):59. doi:10.1186/s40425-016-0165-6
   PubMed Web of Science ®Google Scholar
• van der Leun AM, Thommen DS, Schumacher TN. CD8(+) T cell states in human cancer: insights from single-cell analysis. Nat Rev Cancer. 2020;20(4):218–232. doi:10.1038/s41568-019-0235-4
   PubMed Web of Science ®Google Scholar
• Farhood B, Najafi M, Mortezaee K. CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol. 2019;234(6):8509–8521. doi:10.1002/jcp.27782
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li L, Zheng W, Zhang L, Yao N. CD8(+) T-cell exhaustion in the tumor microenvironment of head and neck squamous cell carcinoma determines poor prognosis. Ann Transl Med. 2022;10(6):273. doi:10.21037/atm-22-867
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Kinoshita J, Saito H, et al. High CD8/CD33 ratio in peritoneal metastatic lesions is associated with favorable prognosis in gastric cancer. Cancer Rep Us. 2021;4(5):e1389. doi:10.1002/cnr2.1389
   Google Scholar
• Rahir G, Moser M. Tumor microenvironment and lymphocyte infiltration. Cancer Immunol Immun. 2012;61(6):751–759. doi:10.1007/s00262-012-1253-1
   PubMed Web of Science ®Google Scholar
• Paijens ST, Vledder A, de Bruyn M, Nijman HW. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol Immunol. 2021;18(4):842–859. doi:10.1038/s41423-020-00565-9
   PubMed Web of Science ®Google Scholar
• Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016;17(12):e542–e551. doi:10.1016/S1470-2045(16)30406-5
   PubMed Web of Science ®Google Scholar
• Baba Y, Nomoto D, Okadome K, et al. Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma. Cancer Sci. 2020;111(9):3132–3141. doi:10.1111/cas.14541
   PubMed Web of Science ®Google Scholar
• Tay C, Tanaka A, Sakaguchi S. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy. Cancer Cell. 2023;41(3):450–465. doi:10.1016/j.ccell.2023.02.014
   PubMed Web of Science ®Google Scholar
• Nakanishi Y, Lu B, Gerard C, Iwasaki A. CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature. 2009;462(7272):510–513. doi:10.1038/nature08511
   PubMed Web of Science ®Google Scholar
• Castellino F, Huang AY, Altan-Bonnet G, Stoll S, Scheinecker C, Germain RN. Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature. 2006;440(7086):890–895. doi:10.1038/nature04651
   PubMed Web of Science ®Google Scholar
• Wong SB, Bos R, Sherman LA. Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells. J Immunol. 2008;180(5):3122–3131. doi:10.4049/jimmunol.180.5.3122
   PubMed Web of Science ®Google Scholar
• Barve SS, Kelkar SV, Gobejishvilli L, Joshi-Barve S, McClain CJ. Mechanisms of alcohol-mediated CD4+ T lymphocyte death: relevance to HIV and HCV pathogenesis. Front Biosci. 2002;7:d1689–d1696. doi:10.2741/A872
   PubMed Web of Science ®Google Scholar
• Hu S, Lu H, Xie W, et al. TDO2+ myofibroblasts mediate immune suppression in malignant transformation of squamous cell carcinoma. J Clin Invest. 2022;132(19). doi:10.1172/JCI157649
   Web of Science ®Google Scholar